AN2 Therapeutics Inc (NASDAQ:ANTX) — Stock Price
AN2 Therapeutics Inc (NASDAQ:ANTX) is currently trading at $5.09 USD, up 1.60% today. Over the past 52 weeks, shares have ranged between $1.03 and $6.28. This page tracks AN2 Therapeutics Inc's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see ANTX operating cash flow.
AN2 Therapeutics Inc (ANTX) Stock Price Chart — Daily History & Trading Volume
The chart below tracks AN2 Therapeutics Inc's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
AN2 Therapeutics Inc Income Statement — Revenue, Profit & Earnings by Year
AN2 Therapeutics Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | — | — | — | $77.00K | — |
| Gross Profit | — | — | — | $-77.00K | — |
| Research & Development | $24.77 Million | $40.49 Million | $54.87 Million | $29.51 Million | $16.91 Million |
| SG&A | $13.34 Million | $14.07 Million | $14.76 Million | $12.75 Million | $4.67 Million |
| Total Operating Expenses | $38.11 Million | $54.55 Million | $69.64 Million | $42.26 Million | $21.57 Million |
| Operating Income | $-38.11 Million | $-54.55 Million | $-69.64 Million | $-42.26 Million | $-21.57 Million |
| EBITDA | $-35.17 Million | $3.23 Million | $4.90 Million | $-43.47 Million | $-21.47 Million |
| EBIT | — | $-51.32 Million | $-64.73 Million | $-42.26 Million | $-21.57 Million |
| Interest Expense | — | — | — | $514.00K | $69.00K |
| Income Before Tax | $-35.17 Million | $-51.32 Million | $-64.73 Million | $-40.96 Million | $-21.54 Million |
| Income Tax Expense | — | — | $-69.64K | $514.00K | $-69.00K |
| Net Income | $-35.17 Million | $-51.32 Million | $-64.73 Million | $-41.47 Million | $-21.47 Million |
AN2 Therapeutics Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes AN2 Therapeutics Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $61.95 Million | $92.09 Million | $138.74 Million | $102.56 Million | $65.32 Million |
| Total Current Assets | $59.94 Million | $86.26 Million | $110.51 Million | $98.62 Million | $60.11 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $38.06 Million | $62.27 Million | $91.65 Million | $68.84 Million | $46.46 Million |
| Net Receivables | $900.00K | $300.00K | $1.40 Million | — | — |
| Inventory | — | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $8.89 Million | $10.24 Million | $14.04 Million | $7.19 Million | $3.41 Million |
| Total Current Liabilities | $8.72 Million | $10.24 Million | $14.04 Million | $7.19 Million | $3.40 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-19.94 Million | $-21.35 Million | $-15.65 Million | $-27.17 Million | $-12.10 Million |
| Total Stockholder Equity | $53.06 Million | $81.85 Million | $124.70 Million | $95.37 Million | $61.91 Million |
| Retained Earnings | $-240.95 Million | $-205.78 Million | $-154.46 Million | $-89.72 Million | $-47.38 Million |
AN2 Therapeutics Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how AN2 Therapeutics Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-29.83 Million | $-49.26 Million | $-53.29 Million | $-33.46 Million | $-20.48 Million |
| Capital Expenditures | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Free Cash Flow | $-29.83 Million | $-49.26 Million | $-53.29 Million | $-33.46 Million | $-20.48 Million |
| Investing Cash Flow | $28.31 Million | $54.59 Million | $-43.28 Million | $-21.77 Million | $-50.02 Million |
| Financing Cash Flow | $113.00K | $372.00K | $84.99 Million | $70.36 Million | $78.53 Million |
| Dividends Paid | — | — | — | $1.82 Million | — |
| Stock-Based Compensation | $6.25 Million | $8.34 Million | $8.41 Million | $4.39 Million | $974.00K |
| Depreciation | — | — | — | $-692.00K | — |
| Change in Cash | $-1.41 Million | $5.70 Million | $-11.57 Million | $15.12 Million | $8.03 Million |
AN2 Therapeutics Inc Earnings History — EPS Actual vs. Analyst Estimates
Track AN2 Therapeutics Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Aug 11, 2026 | -0.18 | -0.24 | +25.00% |
| May 11, 2026 | -0.29 | -0.23 | -26.09% |
| Mar 18, 2026 | -0.29 | -0.24 | -20.83% |
| Nov 12, 2025 | -0.31 | -0.22 | -40.91% |
| Aug 14, 2025 | -0.21 | -0.31 | +32.26% |
| May 13, 2025 | -0.35 | -0.27 | -29.63% |
| Mar 25, 2025 | -0.25 | -0.27 | +7.41% |
| Nov 13, 2024 | -0.35 | -0.39 | +10.26% |